

INDEX

A

- Abdominal desmoid tumors (*see* Desmoid, tumors, abdominal)
- ABO blood group compatibility: in heart transplant, *Sept.*, 621-622
- Achalasia: and esophageal carcinoma, *July*, 484
- Acyclovir: in posttransplant lymphoproliferative disorder, *June*, 415
- Adenocarcinoma
 esophagus, incidence and etiology of, *July*, 485-487
 pancreatoduodenectomy for, results of, *May*, 359
- Age
 as contraindication to heart transplant, *Sept.*, 618-619
 desmoid tumor distribution by, *Apr.*, 264-267, 268-269
 desmoid tumor growth rate and, *Apr.*, 271
 desmoid tumor recurrence and, *Apr.*, 304
 donor selection for heart transplant and, *Sept.*, 625
 esophageal carcinoma surgery and mortality, *Aug.*, 544
 at onset of esophageal carcinoma, *July*, 487
- AIDS: lymphoid tumors in, *June*, 384-385
- Allen test, *Feb.*, 81-82
 false-positive result, *Feb.*, 83
 normal result, *Feb.*, 83
- Allogeneic response: recognized sites of immunosuppressant action in, *June*, 388
- c-AMP: prostaglandins and transplantation, *Nov.*, 735-736
- Angiography: of desmoid tumor in gluteal region, *Apr.*, 291
- Anomalies in desmoid tumor patients
 bone, inherited, *Apr.*, 281-285
 radiologic, *Apr.*, 277
 localization of, *Apr.*, 279
- Antibiotic prophylaxis: for overwhelming postsplenectomy infections, *Dec.*, 805-806
- Antibody
 molecule, schematic of, *June*, 443
 monoclonal, OKT3, in transplantation, *June*, 387, 389
- Anticancer drugs: in desmoid tumors, *Apr.*, 300-301
- Antigen(s)
 immunoglobulin response to, after splenectomy, *Dec.*, 775-777
 -presenting cells, and prostaglandins, *Nov.*, 736
 stimulation, allograft, prostaglandin release by, *Nov.*, 733
- Anti-inflammatory drugs: nonsteroidal, in desmoid tumors, *Apr.*, 301
- Antilymphocyte globulin: Minnesota, in transplantation, *June*, 389
- Antithymocyte globulin: rabbit, in heart transplantation, *Sept.*, 650
- Arrhythmias: due to pulmonary artery catheterization, *Feb.*, 111-114
- Arteries
 axillary (*see* Axillary artery)
 blood sampling, complications of, *Feb.*, 92
 brachial (*see* Brachial, artery)
 brachiocephalic (*see* Brachiocephalic, artery)
 carotid, in desmoid tumor patient, *Apr.*, 298
 catheters, *Feb.*, 80
 digital, occlusion due to radial artery catheterization, *Feb.*, 86, 87
 femoral, catheterization, complications of, *Feb.*, 90-91

Arteries (cont.)

- gastric, left, nodal metastases from esophageal carcinoma along, *Aug.*, 561
 - gastroduodenal, in pancreaticoduodenal resection, *May*, 343
 - hepatic (see Hepatic, arteries)
 - phlebotomy, complications of, *Feb.*, 92
 - pressure monitoring, *Feb.*, 77-92
 - site selection, *Feb.*, 81-82
 - pulmonary (see Pulmonary, artery)
 - pulse-pressure wave tracings, *Feb.*, 79
 - radial (see Radial artery)
 - small (see Vaso-occlusive disorders of upper extremity, small artery)
 - splenic, major branches of, *Dec.*, 762
 - subclavian (see Subclavian, artery)
 - ulnar, thrombosis, digital vessels in, *Jan.*, 27
 - vertebral, laceration due to attempted central venous catheterization, *Feb.*, 96
- Arteriography
- mesenteric
 - portal vein anatomy on, *Mar.*, 164
 - in portal vein thrombosis, *Mar.*, 207
 - in small artery occlusive disorders of upper extremity, *Jan.*, 15-17
 - interpretation of, *Jan.*, 16-17
 - technical considerations, *Jan.*, 16
 - splenic
 - portal venous anatomy on, *Mar.*, 165
 - in splenic injuries, *Dec.*, 770-771
- Arteriosclerosis: accelerated graft, after heart transplant, *Sept.*, 659-660
- Arteritis
- axillary artery in, *Jan.*, 37-39

- giant cell, axillary and subclavian arteries in, *Jan.*, 39
- Arthritis: rheumatoid, digital vessels of upper extremity in, *Jan.*, 23
- Ascites, *Mar.*, 214-217
- evaluation of, *Mar.*, 215
 - management of
 - medical, *Mar.*, 215-216
 - surgical, *Mar.*, 216
 - pathogenesis of, *Mar.*, 215
- Atherosclerosis: digital vessels of upper extremity in, *Jan.*, 20
- Atrioventricular block: during pulmonary artery catheterization, *Feb.*, 113
- Axillary artery
- catheterization, complications of, *Feb.*, 91-92
 - occlusion, *Jan.*, 37-42
 - in arteritis, *Jan.*, 37-39
 - in arteritis, giant cell, *Jan.*, 39
 - embolic, *Jan.*, 40-41
 - irradiation injury causing, *Jan.*, 39-40
 - operative approach, *Jan.*, 41-42
 - trauma causing occlusion, *Jan.*, 40
- Axillosubclavian vein repair: in Paget-Schroetter syndrome, transclavicular approach for, *Jan.*, 58-59
- Azathioprine: in heart transplantation, *Sept.*, 649-650

B

- Billingham criteria: for diagnosing rejection by endomyocardial biopsy, *Sept.*, 652
- Biochemical evaluation: of variceal bleeding, *Mar.*, 161
- Biologic role: of prostaglandins, *Oct.*, 683
- Biopsy
- endomyocardial, in cardiac rejection, *Sept.*, 651-654
 - liver, in variceal bleeding, *Mar.*, 162-163

Bleeding (*see* Variceal bleeding)

Block: atrioventricular, during pulmonary artery catheterization, *Feb.*, 113

Blood

cellular changes after splenectomy, *Dec.*, 778

dyscrasias, digital vessels of upper extremity in, *Jan.*, 25

group compatibility in heart transplant: ABO, *Sept.*, 621-622

sampling, arterial, complications of, *Feb.*, 92

transfusion-induced immunosuppression, and prostaglandins, *Nov.*, 739

Bone

anomalies, inherited, and desmoid tumor, *Apr.*, 281-285

resorption, and prostaglandins, *Oct.*, 690-691

Bony metastases: and prostaglandins, *Oct.*, 693-694

Bougienage: in advanced carcinoma of esophagus and cardia, *Aug.*, 580-581

Bowel posttransplant lymphoproliferative disorder: after renal transplant, *June*, 421, 422

Brachial

artery

catheterization, complications of, *Feb.*, 92

occlusion, *Jan.*, 42-44

pressure assessment, Doppler flow detector for, *Jan.*, 12

thrombus (*see* Thrombus, brachial artery)

plexus, desmoid tumor around, strategy for removal of, *Apr.*, 295

Brachiocephalic

artery occlusion, *Jan.*, 29-44

anatomical considerations, *Jan.*, 29-30

pressure measurements in, *Jan.*, 14

vessels, reconstructive techniques using, *Jan.*, 32

Brain death

criteria for, *Sept.*, 625

heart transplant and, *Sept.*, 625, 628-629

Breast masses: female, 16-keto-PGF_{1α} and thromboxane in, *Oct.*, 695

Brunschwig's pancreatoduodenectomy, *May*, 332

Budd-Chiari syndrome, *Mar.*, 209-214

evaluation of, *Mar.*, 210-211

management of, *Mar.*, 212-214

pathology of, *Mar.*, 210

shunt for, mesoatrial, *Mar.*, 213

Buerger's disease: digital vessels of upper extremity in, *Jan.*, 25

Bullae: due to radial artery catheterization, *Feb.*, 89

Burkitt's lymphoma, *June*, 380-381

Bypass procedures: for advanced carcinoma of esophagus and cardia, *Aug.*, 582-585

C

Cachexia: as contraindication to heart transplant, *Sept.*, 620

Calcium channel blockers: for vasospastic disorders of upper extremity, *Jan.*, 28

Cancer

(*See also* Carcinoma)

as contraindication to heart transplant, *Sept.*, 621

heart and neck, and esophageal carcinoma, *July*, 485

immune system and, historical considerations, *June*, 373-376

prostaglandins and, *Oct.*, 683-700

immune system and, *Oct.*, 689-690

Carcinoma

(*See also* Cancer)

adenocarcinoma (*see* Adenocarcinoma)

Carcinoma, esophagus and cardia,

July, 481-531; *Aug.*, 541-605

advanced

bougienage for, *Aug.*, 580-581

bypass procedures for, *Aug.*,
582-585

intubation for, *Aug.*, 581-582,
583

laser therapy for, *Aug.*, 586-587

palliative therapy for, *Aug.*,
580-587

radiotherapy for, *Aug.*, 585-586

algorithm of surgical oncology

decisions in management of,
July, 507

cervical

esophagolaryngectomy for,
completed, *Aug.*, 558

radiotherapy for, survival after,
Aug., 552

surgery for, *Aug.*, 551-558

surgery for, operative tech-
nique, *Aug.*, 554-557

surgery for, results of, *Aug.*,
557-558

surgery for, survival after, *Aug.*,
552

swallowing ability after thera-
pies for, *Aug.*, 553

chemotherapy for, combined
with radiotherapy, *Aug.*,
594-595

classification of primary tumor,
July, 493-497

determining stage of disease, *July*,
499-501

dysphagia in (*see* Dysphagia in
esophageal carcinoma)

electrical coagulation therapy for,
Aug., 587

esophagogastrectomy for (*see*
Esophagogastrectomy for
carcinoma of esophagus and
cardia)

FEV₁ and, *Aug.*, 543

lymph node involvement in, clas-
sification of, *July*, 497-499

metastases from, distant organ,
classification of, *July*, 499

pathology of, *July*, 490-492

performance status classification,

July, 502

perioperative supportive mea-
sures, *Aug.*, 545-549

postsurgical resection classifica-
tion, *July*, 500

preoperative evaluation, *Aug.*,
542-549

presentation of, *July*, 487-489
age at, *July*, 487

prognostic factors, incidence of
tumor size and relationship
of tumor size to, *July*, 505

radiotherapy for, combined with
chemotherapy, *Aug.*, 594-595

radiotherapy for, postoperative,
Aug., 592

radiotherapy for, preoperative,
Aug., 587-591

"downstaging" and, *Aug.*, 590
effect on operative mortality,

Aug., 590

effect on resectability, *Aug.*, 588
effect on treatment morbidity,

Aug., 591

protocol, *Aug.*, 588

results of studies, *Aug.*, 589

survival and, *Aug.*, 591

radiotherapy for, vs. surgery, *July*,
508-510

resection for

(*See also* Esophagogastrectomy)
combined with chemotherapy,
Aug., 592-595

en bloc, curative, extent of,
July, 514-519

en bloc, curative vs. palliative,
July, 510-512

in smokers, *July*, 483

squamous cell, incidence and
etiology of, *July*, 481-485

staging of, *July*, 492-504

surgery of

classification and, *July*, 507-508
current controversies, *July*,
507-522

effect of tumor location on
choice of procedure, *Aug.*,
549-551

history of, *Aug.*, 541-542

- mortality of, and age, *Aug.*, 544
- physiologic assessment and, *Aug.*, 542-545
- vs. radiotherapy, *July*, 508-510
- therapy for, combination, *Aug.*, 587-595
- thoracic
- clinical approach to, *July*, 504-507
 - en bloc resection for, *Aug.*, 570-580
 - en bloc resection for, operative technique, *Aug.*, 572-576
 - en bloc resection for, postoperative classification after, *Aug.*, 578
 - en bloc resection for, reconstruction of GI tract with left colon interposition after, *Aug.*, 575
 - en bloc resection for, results of, *Aug.*, 576-580
 - staging for, intraoperative, *July*, 501-504
 - surgery for, *Aug.*, 559-580
 - survival after various therapies for, *Aug.*, 577
- Carcinoma: Walker, effects of cyclooxygenase inhibition on, *Oct.*, 693
- Cardia (see Carcinoma, esophagus and cardia)
- Cardiac (see Heart)
- Cardiectomy: view of recipient cuffs and great vessels after, *Sept.*, 630
- Carotid artery: in desmoid tumor patient, *Apr.*, 298
- Catheter(s)
- arterial, *Feb.*, 80
 - jejunostomy feeding, method of securing, *Aug.*, 549
 - pulmonary artery, *Feb.*, 101-102
 - entanglement, *Feb.*, 110-111
 - kinking, *Feb.*, 108
 - knotting, *Feb.*, 110-111
 - migration from time of insertion to 6 hours later, *Feb.*, 106
 - movement of distal portion from balloon deflated to balloon inflated, *Feb.*, 105
 - related infections, *Feb.*, 126-129
 - identification of, *Feb.*, 125-126
- Catheterization
- axillary artery, complications of, *Feb.*, 91-92
 - brachial artery, complications of, *Feb.*, 92
 - cardiac, brachial artery thrombus after, *Jan.*, 44
 - central venous, *Feb.*, 92-97
 - complications of, *Feb.*, 94-97
 - indications for, *Feb.*, 93
 - femoral artery, complications of, *Feb.*, 90-91
 - jugular vein, internal, complications of, *Feb.*, 95-97
 - pulmonary artery, *Feb.*, 97-124
 - arrhythmias due to, *Feb.*, 111-114
 - artifacts, *Feb.*, 108-110
 - atrioventricular block during, *Feb.*, 113
 - complications of, *Feb.*, 105-123
 - complications of, frequency of, *Feb.*, 106-107
 - complications of, at insertion sites, *Feb.*, 107-108
 - embolic fragments, *Feb.*, 110-111
 - errors, *Feb.*, 108-110
 - indications for, *Feb.*, 100-101
 - intracardiac lesions due to, *Feb.*, 114-116, 117, 118
 - lack of correlation between PAWP and left ventricular end diastolic volume during, *Feb.*, 123-124
 - passage of flow-directed balloon catheter, strip chart pressure recording of, *Feb.*, 99
 - perforation of pulmonary artery due to, *Feb.*, 116-120
 - pneumonectomy and, *Feb.*, 123
 - removal, ventricular tachycardia during, *Feb.*, 114
 - site selection, *Feb.*, 102

Catheterization (*cont.*)

- tachycardia during, sinus, *Feb.*, 113
 - technique, *Feb.*, 102-105
 - thrombotic vegetations on tricuspid valve and endocardium due to, *Feb.*, 116
 - thrombus formation due to, *Feb.*, 120-123
 - tricuspid valve erosion due to, *Feb.*, 115
 - radial artery, complications of, *Feb.*, 81-90
 - of splenorenal shunt, distal, in variceal bleeding, *Mar.*, 167
 - subclavian vein, complications of, *Feb.*, 94-97
- Cattell's pancreaticoduodenal resection technique, *May*, 332
- Caustic strictures: and esophageal carcinoma, *July*, 484
- Celiac disease: and esophageal carcinoma, *July*, 484-485
- Cell(s)
- antigen-presenting, and prostaglandins, *Nov.*, 736
 - giant (*see* Giant cell)
 - mediated immune response, mechanism of suppression by prostaglandins, *Nov.*, 735-739
 - suppressor, transplantation and prostaglandins, *Nov.*, 739
 - tumor (*see* Tumor, cell)
- Cellular
- changes in blood after splenectomy, *Dec.*, 778
 - immune interactions, and posttransplant lymphoproliferative disorders, *June*, 438-443
- Central venous catheterization (*see* Catheterization, central venous)
- Chemotherapy: for carcinoma of esophagus and cardia, *Aug.*, 592-595
- Child's classification: of variceal bleeding, *Mar.*, 161-162
- Children
- fibromatosis in, *Apr.*, 243-244

- fibrosarcoma in, *Apr.*, 244
- posttransplant lymphoproliferative disorders in, case presentations, *June*, 417-423, 425-433

Choledochojejunostomy, *May*, 352

Circulatory shock: pharmacologic modulation by prostaglandins, *Nov.*, 723-725

Clonal composition of posttransplant lymphoproliferative disorders, *June*, 400-403

DNA techniques in, *June*, 450-454

Clonality of posttransplant lymphoproliferative disorders (*see* Posttransplant lymphoproliferative disorders, clonality of)

Coagulation therapy: electrical, for carcinoma of esophagus and cardia, *Aug.*, 587

Coccidioidomycosis: after heart transplant, *Sept.*, 659

Collagen

- in desmoid tumors, *Apr.*, 250
- vascular disorder, fingertip gangrene in, *Jan.*, 20

Collateral veins: in thoracic outlet syndrome, *Jan.*, 51

Colon

- ascending, desmoid tumor in, *Apr.*, 293
- as esophageal substitute after esophagogastrectomy, *July*, 519-522

- interposition, left, for GI reconstruction after esophageal en bloc resection, *Aug.*, 575
- manifestations of Gardner's stigmata in desmoid tumor patients, *Apr.*, 275-280

Computed tomography (*see* Tomography, computed)

Connective tissue

- in desmoid tumors, *Apr.*, 251
- disorders, digital vessels of upper extremity in, *Jan.*, 18, 19

Corticosteroids: in heart transplantation, *Sept.*, 648-649

CT (*see* Tomography, computed)

Cyclooxygenase inhibition: effects on Walker carcinosarcoma, *Oct.*, 693
 Cyclosporine: in heart transplantation, *Sept.*, 644-648
 Cytoimmunologic monitoring: in diagnosis of acute cardiac rejection, *Sept.*, 655
 Cytotoxic screen: In heart transplantation, *Sept.*, 622

D

Death (*see* Mortality)
 Decompression, selective, for variceal bleeding, *Mar.*, 177-183
 for prevention of recurrent bleeding, *Mar.*, 201-202
 Dermatofibroma: differentiated from desmoid tumor, *Apr.*, 255
 Dermatologic complications: after heart transplant, *Sept.*, 661
 Desjardins' technique: for pancreaticojejunostomy, *May*, 329
 Desmoid
 syndrome, *Apr.*, 233-320
 (*See also* Desmoid, tumors)
 tissue, sex steroid hormone receptors in, *Apr.*, 285-289
 tumors
 abdominal, clinical appearance of, *Apr.*, 241
 abdominal, localization of, *Apr.*, 264
 age distribution, *Apr.*, 264-267, 268-269
 anatomical distribution of, *Apr.*, 263-264
 bone anomalies and, inherited, *Apr.*, 281-285
 around brachial plexus, strategy for removal of, *Apr.*, 295
 classification of, *Apr.*, 243-249
 collagen in, *Apr.*, 250
 in colon, ascending, *Apr.*, 293
 congenital, *Apr.*, 244
 connective tissue in, *Apr.*, 251
 diagnosis, differential, *Apr.*, 249-255

drugs in, anticancer, *Apr.*, 300-301
 drugs in, nonsteroidal anti-inflammatory, *Apr.*, 301
 etiology of, *Apr.*, 267-275
 extra-abdominal, clinical appearance of, *Apr.*, 241
 extra-abdominal, differential diagnosis of, *Apr.*, 254-255
 extra-abdominal, localization of, *Apr.*, 264
 extra-abdominal, microscopic characteristics of, *Apr.*, 254
 familial, *Apr.*, 244-248
 Gardner's stigmata in, colonic and extracolonic manifestations of, *Apr.*, 275-280
 in gluteal region, angiography of, *Apr.*, 291
 growth behavior of, *Apr.*, 267-275
 growth rate in different age groups, *Apr.*, 266-267
 hip in, *May*, 280
 histologic features of, *Apr.*, 249
 hormonal constitution of female patients and, *Apr.*, 267-274
 in ileal mesentery, *Apr.*, 294
 in ileum, terminal, *Apr.*, 293
 incidence of, *Apr.*, 259-262
 inflammatory focus in periphery of, *Apr.*, 252
 in infraclavicular region, *Apr.*, 297
 inguinal region, right, preoperative strategy for removal of, *Apr.*, 293
 malignant transformation, *Apr.*, 255-259
 mitoses in, *Apr.*, 253
 myxomatously degenerated area in, *Apr.*, 252
 osteoma of jaw in, *Apr.*, 278
 pathology of, *Apr.*, 249
 peroperative strategy, *Apr.*, 291-300
 pregnancy and, *Apr.*, 267-274
 preoperative planning, *Apr.*, 290-300

Desmoid (cont.)

- progesterone and, *Apr.*, 288-289
- radiologic anomalies in, *Apr.*, 277
- radiologic anomalies in, localization of, *Apr.*, 279
- radiotherapy for, *Apr.*, 300
- radiotherapy for, combined with surgery, complications after, *Apr.*, 306
- radius in, cortical thickening of, *Apr.*, 279
- recurrence according to age, *Apr.*, 304
- recurrence according to anatomic region, *Apr.*, 304
- recurrence according to operational access, *Apr.*, 304
- recurrence in irradiated area, strategy for removal, *Apr.*, 296
- recurrence, success rate in sequential attempts to eradicate, *Apr.*, 305
- recurrence after therapy, *Apr.*, 303
- in retroperitoneal area, CT of, *Apr.*, 292
- sarcolemmal giant cells in, *Apr.*, 250
- in supraclavicular region, *Apr.*, 297
- surgery for, *Apr.*, 289-290
- surgery for, combined with radiotherapy, complications after, *Apr.*, 306
- surgery for, complications after, *Apr.*, 306
- teeth and, *Apr.*, 278
- trauma and, *Apr.*, 274-275
- treatment of, *Apr.*, 289-307
- ultrastructural investigation of, *Apr.*, 249
- Devascularization procedures for variceal bleeding, *Mar.*, 183-184
- for prevention of recurrent bleeding, *Mar.*, 203
- Diabetes mellitus: as contraindication to heart transplant, *Sept.*, 620

Diarrhea: PGE and PGF levels in, *Oct.*, 696

Digital

- artery occlusion due to radial artery catheterization, *Feb.*, 86, 87
- ischemia, upper extremity drug-induced, *Jan.*, 26
- primary arterial causes of, *Jan.*, 30
- systemic diseases causing, *Jan.*, 11
- vessel occlusion, upper extremity in atherosclerosis, *Jan.*, 20
- in blood dyscrasias, *Jan.*, 25
- in Buerger's disease, *Jan.*, 25
- calcium channel blockers for, *Jan.*, 28
- in connective tissue disorders, *Jan.*, 18, 19
- diseases causing, *Jan.*, 18-29
- in lupus erythematosus, systemic, *Jan.*, 23-24
- in occupational trauma, *Jan.*, 26-27
- in polyarteritis nodosa, *Jan.*, 24-25
- in rheumatoid arthritis, *Jan.*, 23
- in scleroderma, *Jan.*, 18-20
- sympathectomy for, *Jan.*, 28-29
- therapy for, *Jan.*, 27-29
- therapy for, medical, *Jan.*, 27-28
- therapy for, operative, *Jan.*, 28-29
- in ulnar artery thrombosis, *Jan.*, 27
- in vasculitis (see Vasculitis, upper extremity digital vessels in)
- Di-M-PGE₂: and melanoma growth in vivo, *Oct.*, 697-700
- Dizziness: orthostatic, and heart transplant, *Sept.*, 661
- DNA techniques: in posttransplant lymphoproliferative disorders, *June*, 447-448, 450-454
- Doppler flow detector, *Jan.*, 12

Drug(s)

- anticancer, in desmoid tumors, *Apr.*, 300-301
- ischemia due to, upper extremity, *Jan.*, 26
- nonsteroidal anti-inflammatory, in desmoid tumors, *Apr.*, 301
- therapy for variceal bleeding, *Mar.*, 168-169
- for prevention of recurrent bleeding, *Mar.*, 194-195

Duodenum

- (See also Pancreaticoduodenal resection)
- site of severance in pylorus-preserving procedure, *May*, 344
- Dyscrasias: blood, digital vessels of upper extremity in, *Jan.*, 25
- Dysphagia in esophageal carcinoma, *July*, 489-490
- diagnosis of
- endoscopic, *July*, 490
- roentgenographic, *July*, 489-490
- functional grades of, *July*, 503

E

- Edema: due to radial artery catheterization, *Feb.*, 89

Eicosanoids

- actions of, *Oct.*, 681-682
- degradation of, *Oct.*, 680
- discussion of term, *Oct.*, 679
- synthesis of, *Oct.*, 680
- tumor cells in vitro and, *Oct.*, 683-689
- tumors in vivo and, *Oct.*, 694-700

- Electrical coagulation therapy: for carcinoma of esophagus and cardia, *Aug.*, 587

- Electrocardiogram frequency analysis: surface, in diagnosis of acute cardiac rejection, *Sept.*, 656

- Electrophysiology: of transplanted heart, *Sept.*, 635-636

Embolism

- fragments from pulmonary artery catheterization, *Feb.*, 110-111

- occlusion of axillary artery, *Jan.*, 40-41

- Embolism: after radial artery catheterization, *Feb.*, 86

- Endocardium: thrombotic vegetation due to pulmonary artery catheterization, *Feb.*, 116

- Endomyocardial biopsy: in cardiac rejection, *Sept.*, 651-654

Endoscopy

- in dysphagia in esophageal carcinoma, *July*, 490

- landmarks of esophagus, *July*, 493
- sclerotherapy via (see Sclerotherapy, endoscopic variceal)
- in variceal bleeding, *Mar.*, 162
- acute, *Mar.*, 191

- Equipment: invasive monitoring mechanical, and infection, *Feb.*, 129-130

- Epigastrium: posttransplant lymphoproliferative disorder in, *June*, 429, 430

Epstein-Barr virus

- associated posttransplant lymphoproliferative disorders, *June*, 385-389

- biology, *June*, 376-379
- infection, *June*, 376-379
- neoplasia and, *June*, 376-409

- Esophagogastrrectomy for carcinoma of esophagus and cardia

- en bloc, outline of boundaries for abdominal and thoracic portions of, *July*, 517

- stomach vs. colon as esophageal substitute after, *July*, 519-522
- transhiatal, *Aug.*, 566-570

- operative technique, *Aug.*, 566-569

- results of, *Aug.*, 569-570
- vs. transthoracic, *July*, 512-514

- transthoracic, *Aug.*, 560-566
- operative technique, *Aug.*, 560-565

- reconstruction of gastrointestinal continuity after, *Aug.*, 563

- results of, *Aug.*, 565-566

Esophagogastrectomy for carcinoma of esophagus and cardia (*cont.*)
 vs. transhiatal, *July*, 512-514
 Esophagolaryngectomy: completed, *Aug.*, 558
 Esophagus
 adenocarcinoma, incidence and etiology of, *July*, 485-487
 axis abnormalities, *July*, 495
 cancer (*see* Carcinoma, esophagus and cardia)
 carcinoma (*see* Carcinoma, esophagus and cardia)
 endoscopic landmarks of, *July*, 493
 lymphatic drainage of, *July*, 498
 substitute after esophagogastrectomy, stomach vs. colon for, *July*, 519-522
 varices (*see* Variceal bleeding)
 Extremities, upper
 digital ischemia of (*see* Digital, ischemia, upper extremity)
 digital vessels of (*see* Digital, vessel occlusion, upper extremity)
 hypercoagulable states (*see* Hypercoagulable states)
 vaso-occlusive disorders of (*see* Vaso-occlusive disorders of upper extremity)
 veno-occlusive disorders of, *Jan.*, 44-60
 iatrogenic, *Jan.*, 47-48

F

Fatty acids: essential, prostaglandins, and transplantation, *Nov.*, 739-740
 Feeding jejunostomy (*see* Jejunostomy, feeding)
 Femoral artery catheterization: complications of, *Feb.*, 90-91
 FEV₁: and surgery of esophageal carcinoma, *Aug.*, 543
 Fibrinolytic therapy (*see* Paget-Schroetter syndrome, fibrinolytic therapy for)

Fibromatosis, *Apr.*, 243
 classification of, *Apr.*, 310-313
 juvenile, *Apr.*, 243-244
 Fibrosarcoma
 differentiated from extra-abdominal desmoid tumor, *Apr.*, 254
 infantile/juvenile, *Apr.*, 244
 low-grade, microscopic characteristics of, *Apr.*, 251
 Finger gangrene: due to radial artery catheterization, *Feb.*, 89
 Fingertip
 gangrene in collagen vascular disorder, *Jan.*, 20
 infarcts in systemic vasculitis, *Jan.*, 24
 FK506: in transplantation, *June*, 389

G

Gangrene
 finger, due to radial artery catheterization, *Feb.*, 89
 fingertip, in collagen vascular disorder, *Jan.*, 20
 Gardner's syndrome, *Apr.*, 248-249
 in desmoid tumor patients, colonic and extracolonic manifestations of, *Apr.*, 275-280
 Gastric
 artery, left, nodal metastases from esophageal carcinoma along, *Aug.*, 561
 vessels, short, division for splenectomy, *Dec.*, 815
 Gastrocolic anastomosis: division for anterior approach to splenic vessels, *Dec.*, 817
 Gastroduodenal arteries: in pancreaticoduodenal resection, *May*, 343
 Gastroesophageal varices (*see* Variceal bleeding)
 Gastrointestinal
 (*See also* Stomach)
 continuity, reconstruction after transthoracic esophagectomy, *Aug.*, 563

tract

- anastomoses after pancreaticoduodenal resection, *May*, 353
- in Kaposi's sarcoma in renal transplant recipient, *June*, 435
- reconstruction after esophageal en bloc resection, *Aug.*, 575

Gene rearrangements (*see* Post-transplant lymphoproliferative disorders, gene rearrangements in)

Giant cell(s)

- arteritis, axillary and subclavian arteries in, *Jan.*, 39
- sarcolemmal, in desmoid tumor, *Apr.*, 250

Globulin

- antilymphocyte, Minnesota, in transplantation, *June*, 389
- antithymocyte, rabbit, in heart transplantation, *Sept.*, 650

Gluteal area: desmoid tumor in, angiography of, *Apr.*, 291

H

Head cancer: and esophageal carcinoma, *July*, 485

Heart

- catheterization, brachial artery thrombus after, *Jan.*, 44
 - disease, etiologies leading to transplantation, *Sept.*, 616
 - intracardiac lesions due to pulmonary artery catheterization, *Feb.*, 114-116, 117, 118
 - transplantation (*see* Transplantation, heart)
 - xenografting, *Sept.*, 664
- Hemangioendothelioma: differentiated from desmoid tumor, *Apr.*, 255
- Hemangioma: differentiated from desmoid tumor, *Apr.*, 255
- Hematologic evaluation: of variceal bleeding, *Mar.*, 160-161

Hemodynamic

- effect of endogenous prostaglandins in sepsis and shock, *Nov.*, 722-723
- measurements in variceal bleeding, *Mar.*, 165-167
- monitoring (*see* Monitoring, invasive)

Hemodynamics: of transplanted heart, *Sept.*, 635

Hemostasis: for spleen preservation, *Dec.*, 796-801

Heparin: in Paget-Schroetter syndrome, *Jan.*, 52

Hepatic

(*See also* Liver)

arteries

- at gastroduodenal origin, configuration of, *May*, 343
- in pancreatoduodenectomy, *May*, 342, 343

Hepatocyte function: quantitative, in variceal bleeding, *Mar.*, 167-168

H-graft: portacaval, *Mar.*, 175-176

Hip: in desmoid tumor patient, *May*, 280

Hormone

- constitution of female patients, and desmoid tumors, *Apr.*, 267-274
- sex steroid hormone receptors in desmoid tissue, *Apr.*, 285-289

Humoral induction: of hypercalcemia, and prostaglandins, *Oct.*, 691-692

Hypercalcemia syndromes: and prostaglandins, *Oct.*, 690-694

Hypercoagulable states, upper extremity, *Jan.*, 45-47

- primary, *Jan.*, 46
- secondary, *Jan.*, 45

Hypersensitivity vasculitis, upper extremity digital vessels in, *Jan.*, 23

therapy, *Jan.*, 23

Hypertension (*see* portal, hypertension)

Iatrogenic

immunodeficiency state of organ transplant recipient, *June*, 386-389

splenic injuries, *Dec.*, 763-766

veno-occlusive disorders of upper extremity, *Jan.*, 47-48

ICU

monitoring in (see Monitoring, invasive)

patient, physiologic profile analysis of, *Feb.*, 133

Ileocecal valve: from liver transplant recipient with posttransplant lymphoproliferative disorder, *June*, 394

Ileum

mesentery, desmoid tumors in, *Apr.*, 294

terminal

desmoid tumor in, *Apr.*, 293

posttransplant lymphoproliferative disorder of, *June*, 428

Imaging: magnetic resonance, of cardiac rejection, *Sept.*, 656

Immune

interactions, and posttransplant lymphoproliferative disorders, *June*, 438-454

response, cell-mediated, prostaglandins suppressing, *Nov.*, 735-739

system

cancer and, historical considerations, *June*, 373-376

prostaglandin production by macrophages-monocytes in, *Nov.*, 733-734

prostaglandins and malignancy, *Oct.*, 689-690

Immunity: and heart transplantation, *Sept.*, 638-642

Immunocytochemical techniques: for determination of clonality of posttransplant lymphoproliferative disorders, *June*, 446-447

Immunodeficiency state

iatrogenic, of organ transplant recipient, *June*, 386-389

neoplasms in, *June*, 385

syndrome

acquired, lymphoid tumors in, *June*, 384-385

congenital, lymphoid tumors in, *June*, 382-384

Immunoglobulin(s)

gene rearrangements (see Posttransplant lymphoproliferative disorders, gene rearrangements in, immunoglobulin)

response to antigens after splenectomy, *Dec.*, 775-777

after splenectomy, *Dec.*, 775-777

Immunology: of cardiac rejection, *Sept.*, 637-638

Immunosuppressants

in heart transplantation, *Sept.*, 644-650

recognized sites of action in allogeneic response, *June*, 388

Immunosuppression

blood transfusion-induced, and prostaglandins, *Nov.*, 739

in heart transplantation (see Transplantation, heart, immunosuppression in)

Immunosuppressive effect: of prostaglandins, *Nov.*, 735

Implantation: spleen, *Dec.*, 801-805

Indomethacin

effect on cell replication, *Oct.*, 685

melanoma growth and, in vivo, *Oct.*, 697-699

Infantile fibrosarcoma, *Apr.*, 244

Infarction

finger tip and nail fold, in systemic vasculitis, *Jan.*, 24

pulmonary, unresolved, as contraindication to heart transplant, *Sept.*, 619-620

Infections

catheter-related, *Feb.*, 126-129

identification of, *Feb.*, 125-126

complicating invasive monitoring, *Feb.*, 124-130

after heart transplant (*see* Transplantation, heart, infection after)

lymphoproliferative disorders and, posttransplant, *June*, 412

postsplenectomy (*see* Postsplenectomy infections)

Infraclavicular region: desmoid tumor in, *Apr.*, 297

Inguinal region: right, preoperative strategy for removal of desmoid tumor from, *Apr.*, 293

Injuries (*see* Trauma)

Inotropic support: and heart transplant, *Sept.*, 626

Intensive care unit (*see* ICU)

Interleukin

- 1, prostaglandins and transplantation, *Nov.*, 736-738
- 2, prostaglandins and transplantation, *Nov.*, 738

Intracardiac lesions: due to pulmonary artery catheterization, *Feb.*, 114-116, 117, 118

Intravascular devices: infection complicating, *Feb.*, 124-130

Intubation: for advanced carcinoma of esophagus and cardia, *Aug.*, 581-582, 583

Irradiation (*see* Radiotherapy)

Ischemia (*see* Digital, ischemia)

Isovolumic relaxation time: in diagnosis of acute cardiac rejection, *Sept.*, 654-655

J

Jaw: osteoma in, in desmoid tumor patient, *Apr.*, 278

Jejunostomy

- feeding
- catheter, method of securing, *Aug.*, 549
- portable pump and, *Aug.*, 550
- tube, insertion technique, *Aug.*, 548

Witzel, *Aug.*, 547

Jugular vein catheterization: internal, complications of, *Feb.*, 95-97

Juvenile (*see* Children)

K

Kaposi's sarcoma in renal transplant recipient, *June*, 433-436, 437

- case report, *June*, 434-435
- follow-up GI series, *June*, 437

GI tract in, *June*, 435

skin lesions in, *June*, 434

stomach in, *June*, 436

Kappa light gene rearrangement: in posttransplant lymphoproliferative disorders, *June*, 449

Karyotypic analysis: Of posttransplant lymphoproliferative disorder, *June*, 403-405

Keloid: differentiated from desmoid tumor, *Apr.*, 254, 255

6-Keto-PGF_{1α}: in female breast masses, *Oct.*, 695

Kidney

- dysfunction, irreversible, as contraindication to heart transplant, *Sept.*, 619
- transplant (*see* Kaposi's sarcoma in renal transplant recipient)

Kocher maneuver, *May*, 339

L

Laceration

- pulmonary artery, due to catheterization, *Feb.*, 119
- vertebral artery, due to attempted central venous catheterization, *Feb.*, 96

Laser therapy: of advanced carcinoma of esophagus and cardia, *Aug.*, 586-587

Lavage: peritoneal diagnostic, in splenic injuries, *Dec.*, 769-770

Ligaments

- peritoneal, lateral, division for spleen mobilization, *Dec.*, 818
- splenocolic, division of, *Dec.*, 816
- splenorenal and splenophrenic, division for spleen mobilization, *Dec.*, 812

Lipoma: differentiated from desmoid tumor, *Apr.*, 255

Lipoxygenase products: actions of, *Oct.*, 682

Liver

- biopsy in variceal bleeding, *Mar.*, 162-163
- dysfunction, irreversible, as contraindication to heart transplant, *Sept.*, 619
- transplant (see Transplantation, liver)

Lung (see Pulmonary)

Lupus erythematosus: systemic, digital vessels of upper extremity in, *Jan.*, 23-24

Lymph node

- involvement in esophageal carcinoma
- classification of, *July*, 497-499
- en bloc resection for cure, *July*, 515
- metastases from esophageal carcinoma, *Aug.*, 561

Lymphatic drainage: of esophagus, *July*, 498

Lymphocytes

- in desmoid tumors, *Apr.*, 252
- identification methodologies in posttransplant lymphoproliferative disorders, *June*, 443-445

Lymphoid tumors

- in immunodeficiency syndromes
- acquired, *June*, 384-385
- congenital, *June*, 382-384
- in posttransplant lymphoproliferative disorders
- benign vs. malignant, *June*, 454-457
- progression of, *June*, 455

Lymphoma

- Burkitt's, *June*, 380-381

after cyclosporine in heart transplantation, *Sept.*, 648

Lymphoproliferative disorders (see Posttransplant lymphoproliferative disorders)

M

Macfarlane, J., *Apr.*, 234

Macrophages: in immune system, prostaglandin production by, *Nov.*, 733-734

Magnetic resonance imaging: of cardiac rejection, *Sept.*, 656

Malformations (see Anomalies)

Malignancy (see Cancer)

Mandible: osteoma in, in desmoid tumor patients, *Apr.*, 278

Mediastinitis: after heart transplant, *Sept.*, 658-659

Melanoma growth in vivo: and prostaglandins, *Oct.*, 697-700

Mesenteric arteriography (see Arteriography, mesenteric)

Mesentery: ileal, desmoid tumor in, *Apr.*, 294

Mesoatrial shunt: for Budd-Chiari syndrome, *Mar.*, 213

Mesogastrium: dorsal, spleen development in, *Dec.*, 760

Metastases

bony, and prostaglandins, *Oct.*, 693-694

distant organ, from esophageal carcinoma, classification of, *July*, 499

nodal, from esophageal carcinoma, *Aug.*, 561

Minnesota antilymphocyte globulin: in transplantation, *June*, 389

Mitoses: in desmoid tumor, *Apr.*, 253

Monitoring

arterial pressure, *Feb.*, 77-92

site selection, *Feb.*, 81-82

cytoimmunologic, in diagnosis of acute cardiac rejection, *Sept.*, 655

evolution of, *Feb.*, 75-77

invasive, *Feb.*, 75-145

complications of, *Feb.*, 75-145

infection complicating, *Feb.*,

124-130

mechanical equipment, and infection, *Feb.*, 129-130

role of, *Feb.*, 130-135

Monoclonal antibody OKT3: in

transplantation, *June*, 387, 389

Monocytes: in immune system,

prostaglandin production by,

Nov., 733-734

Mortality

(See also Brain death)

of esophageal carcinoma surgery

age and, *Aug.*, 544

effect of preoperative radiotherapy on, *Aug.*, 590

after heart transplantation, *Sept.*, 616

Muscle: pectoral, in desmoid tumor patient, *Apr.*, 299

Myositis: diffuse subacute, differentiated from desmoid tumor, *Apr.*, 255

Myxomatously degenerated area: of desmoid tumor, *Apr.*, 252

N

Nail fold infarcts: finger, in systemic vasculitis, *Jan.*, 24

Neck cancer: and esophageal carcinoma, *July*, 485

Necrosis: in posttransplant lymphoproliferative disorder, *June*, 396

Neoplasia (see Tumors)

Neurofibroma: differentiated from desmoid tumor, *Apr.*, 255

Nifedipine: in vasospastic disorders of upper extremity, *Jan.*, 28

Nutritional support of esophageal carcinoma patients, *Aug.*, 546-549

portable pump for, *Aug.*, 550

O

Occupational trauma: digital vessels of upper extremity in, *Jan.*, 26-27

Oculopneumoplethysmographic tracing, *Jan.*, 13

OKT3: in transplantation, *June*, 387, 389

Omentum: gastrocolic, division for anterior approach to splenic vessels, *Dec.*, 817

Oncogenes: in posttransplant lymphoproliferative disorder, *June*, 405, 456-457

OPSI (see Postsplenectomy infections, overwhelming)

Orthostatic dizziness: after heart transplant, *Sept.*, 661

Osteoma: in jaw in desmoid tumor patients, *Apr.*, 278

P

Paget-Schroetter syndrome, *Jan.*, 48-60

axillosubclavian vein repair in, transclavicular approach for, *Jan.*, 58-59

diagnosis of, *Jan.*, 49-51

epidemiology of, *Jan.*, 48-49

fibrinolytic therapy for, *Jan.*, 53-56

complications of, *Jan.*, 54-56

contraindications to, *Jan.*, 55

pathophysiology of, *Jan.*, 52

surgery for, *Jan.*, 56-60

therapy for, *Jan.*, 52-60

Pancreas

avascular area under neck of, *May*, 345

successive sectioning illustrating movement of pancreatic duct to center of gland for two-layer anastomosis, *May*, 348

Pancreaticoduodenal resection, *May*, 327-363

for adenocarcinoma, results of, *May*, 359

Brunschwig's technique, *May*, 332

Pancreaticoduodenal resection

(*cont.*)

- Cattell's technique, *May*, 332
 - conduct of operation, *May*, 336-353
 - development of, *May*, 327-335
 - exposure, *May*, 336-337
 - gastroduodenal artery in, *May*, 343
 - hepatic arteries in, *May*, 342, 343
 - intraoperative decisions, *May*, 337-339
 - Kocher maneuver in, *May*, 339
 - for pancreatitis, chronic, results of, *May*, 358
 - patient preparation for, *May*, 335-336
 - plane I in, *May*, 339
 - plane II in, *May*, 341
 - plane III in, *May*, 345
 - plane IV in, *May*, 346
 - postoperative management, *May*, 354-355
 - pylorus-preserving
 - site of severance of duodenum in, *May*, 344
 - Traverso and Longmire's technique, *May*, 334
 - Watson's technique, *May*, 334
 - recent experience with, *May*, 328
 - reconstruction, *May*, 347-353
 - sequence of anastomoses of gastrointestinal tract after completion of, *May*, 353
 - resection technique, *May*, 339-347
 - results of, *May*, 355-360
 - Whipple's technique, *May*, 331
- Pancreaticoduodenectomy (*see* Pancreaticoduodenal resection)
- Pancreaticojejunostomy
(*See also* Pancreaticoduodenal resection)
- Desjardins' technique, *May*, 329
 - dunking, *May*, 351
 - end-to-side
 - initial phase of, *May*, 349
 - posterior half completed, *May*, 350

Pancreatitis

- chronic, results of pancreatoduodenectomy for, *May*, 358
 - after heart transplantation, *Sept.*, 660
- Paraneoplastic syndromes: and prostaglandins, *Oct.*, 695-697
- Pectoral muscle: in desmoid tumor patient, *Apr.*, 299
- Peptic ulcer disease: as contraindication to heart transplant, *Sept.*, 621
- Peritoneal
 - lavage, diagnostic, in splenic injuries, *Dec.*, 769-770
 - ligaments, lateral, division for spleen mobilization, *Dec.*, 818
- Peritoneovenous shunts: in ascites, *Mar.*, 216
- Pharmacologic modulation: of circulatory shock by prostaglandins, *Nov.*, 723-725
- Pharmacotherapy (*see* Drugs)
- Phlebotomy: arterial, complications of, *Feb.*, 92
- Physical examination: in diagnosis of cardiac rejection, *Sept.*, 651
- Physiologic profile analysis: of ICU patient, *Feb.*, 133
- Physiology: of transplanted heart, *Sept.*, 634-637
- Pitressin in variceal bleeding, *Mar.*, 168-169
 - acute, *Mar.*, 191-192
- Plumbing: arterial catheter, *Feb.*, 80
- Pneumectomy: and pulmonary artery catheterization, *Feb.*, 123
- Polyamines: urinary, in diagnosis of acute cardiac rejection, *Sept.*, 655
- Polyarteritis nodosa: digital vessels of upper extremity in, *Jan.*, 24-25
- Portacaval
 - H-graft, *Mar.*, 175-176
 - shunt, end-to-side, schematic of, *Nov.*, 173

Portal

- hypertension, *Mar.*, 155-223
 - etiology of, *Mar.*, 158-159
 - history of, *Mar.*, 155-156
- systemic shunts (see Shunts, portal systemic, total)

vein

- anatomy, *Mar.*, 157-158
- anatomy, on arteriogram, mesenteric, *Mar.*, 164
- anatomy, on arteriogram, splenic, *Mar.*, 165
- thrombosis, extrahepatic (see Variceal bleeding, in portal vein thrombosis, extrahepatic)
- visualization after contrast material, *Mar.*, 166

Postsplenectomy infections, *Dec.*,

779-786

early, *Dec.*, 785-786

overwhelming, *Dec.*, 779-785

antibiotic prophylaxis, *Dec.*, 805-806

prevention of, *Dec.*, 805-810

vaccination causing, *Dec.*, 808-809

vaccination preventing, *Dec.*, 806-808

vaccines available for, *Dec.*, 809

Posttransplant lymphoproliferative disorders, *June*, 371-472

bowel, after renal transplant, *June*, 421, 422

case presentations, *June*, 417-433

clinical considerations, *June*, 409-417

clinical presentation, *June*, 410-412

clonal composition of, *June*, 400-403

DNA techniques in, *June*, 450-454

clonality of

DNA techniques, *June*, 447-448

immunocytochemical techniques, *June*, 446-447

methodologies for, *June*, 446-454

course of, *June*, 412-416

development of, risk factors for, *June*, 389-392

discussion of term, *June*, 372

in epigastrium, *June*, 429, 430

Epstein-Barr virus-associated, *June*, 385-389

gene rearrangement in

immunoglobulin, heavy chain, *June*, 453

immunoglobulin, normal, *June*, 448-450

immunoglobulin, Southern

blotting for, *June*, 451

kappa light, *June*, 449

general summary of, *June*, 372-373

of ileum, terminal, *June*, 428

immune interactions and, *June*, 438-454

infections associated with, *June*, 412

karyotypic analysis of, *June*, 403-405

lymphocyte identification methodologies in, *June*, 443-445

lymphoid tumors in (see Lymphoid tumors, in posttransplant lymphoproliferative disorders)

macroscopic appearance, *June*, 392-395

microscopic appearance, *June*, 395-400

monomorphic, *June*, 399

necrosis in, *June*, 396

oncogene expression in, *June*, 405, 456-457

pathogenesis of, hypothesis for, *June*, 406-409

pathology of, *June*, 392-400

patient population, *June*, 409

polymorphic, *June*, 396-397

minimally, *June*, 398

preliminary comments, *June*, 371-372

pulmonary

chest x-ray in, *June*, 425, 427

clinical course of, *June*, 424

- Posttransplant lymphoproliferative disorders (*cont.*)
 continuing multinodular infiltrates in, *June*, 426
 specimen processing in, *June*, 416-417
 technical considerations related to study of, *June*, 438-457
 therapy, *June*, 412-416
 time of onset, *June*, 409-410
 Pregnancy: and desmoid tumors, *Apr.*, 267-274
 Progesterone: effect on desmoid tumors, *Apr.*, 288-289
 Prolactin: serum, in diagnosis of acute cardiac rejection, *Sept.*, 655-656
 Properdin: after splenectomy, *Dec.*, 777
 Propranolol in variceal bleeding, *Mar.*, 169
 for prevention of recurrent bleeding, *Mar.*, 195
 Prostacyclin
 actions of, *Oct.*, 682
 blockers, *Nov.*, 721
 release during sepsis and shock, *Nov.*, 716-717
 in shock, septic, *Nov.*, 727
 Prostaglandin(s), *Oct.*, 679-706; *Nov.*, 715-747
 analogues, *Oct.*, 682-683
 antigen-presenting cells and, *Nov.*, 736
 biologic role of, *Oct.*, 683
 biosynthesis, *Oct.*, 679-681
 rates related to tumor doubling times, *Oct.*, 686
 blockers, *Nov.*, 721
 bone resorption and, *Oct.*, 690-691
 bony metastases and, *Oct.*, 693-694
 classic, release during sepsis and shock, *Nov.*, 715-716
 differentiation of tumor cells and, *Oct.*, 687-689
 E
 actions of, *Oct.*, 681-682
 in diarrhea, *Oct.*, 696
 E₁, effect on cell replication, *Oct.*, 685
 F
 compounds, actions of, *Oct.*, 681-682
 in diarrhea, *Oct.*, 696
 F_{1a}, 6-keto, in female breast masses, *Oct.*, 695
 formation in sepsis and shock, inhibition of, *Nov.*, 718-722
 humoral induction of hypercalcemia and, *Oct.*, 691-692
 hypercalcemia syndromes and, *Oct.*, 690-694
 I₂ (*see* Prostacyclin)
 immunosuppressive effect of, *Nov.*, 735
 malignancy and, *Oct.*, 683-700
 immune system and, *Oct.*, 689-690
 melanoma growth in vivo and, *Oct.*, 697-700
 metabolism, *Oct.*, 679-681
 nomenclature, *Oct.*, 681
 paraneoplastic syndromes and, *Oct.*, 695-697
 pharmacologic modulation of circulatory shock by, *Nov.*, 723-725
 production
 by macrophages-monocytes in immune system, *Nov.*, 733-734
 by tumor cells, *Oct.*, 683-686
 by tumors, in vivo, *Oct.*, 694-695
 release
 by allograft antigen stimulation, *Nov.*, 733
 during sepsis and shock, *Nov.*, 715-718
 in sepsis, *Nov.*, 715-733
 effects of, *Nov.*, 718-725
 effects of, hemodynamic, *Nov.*, 722-723
 in shock, *Nov.*, 715-733
 effects of, *Nov.*, 718-725
 effects of, hemodynamic, *Nov.*, 722-723
 septic, clinical, *Nov.*, 725-728

suppression of cell-mediated immune response by, *Nov.*, 735-739

in transplantation, *Nov.*, 733-747

c-AMP and, *Nov.*, 735-736

blood transfusion-induced immunosuppression and, *Nov.*, 739

fatty acids and, essential, *Nov.*, 739-740

immunosuppressive effect of, *Nov.*, 735

interleukin-1 and, *Nov.*, 736-738

interleukin-2 and, *Nov.*, 738

release by allograft antigen stimulation, *Nov.*, 633

suppressor cells and, *Nov.*, 739

tumor cell replication and, *Oct.*, 686-687

tumor growth control and, in vivo, *Oct.*, 697-700

Psychosocial complications: of heart transplant, *Sept.*, 661

Pulmonary

artery

catheter (*see* Catheter, pulmonary artery)

catheterization (*see* Catheterization, pulmonary artery)

perforation due to catheter, *Feb.*, 116-120

wedge pressure during catheterization, and left ventricular end diastolic volume, *Feb.*, 123-124

wedge pressure tracing of mechanically ventilated patient, *Feb.*, 109, 110

infarction, unresolved, as contraindication to heart transplant, *Sept.*, 619-620

lesions, undiagnosed radiographic, as contraindication to heart transplant, *Sept.*, 620

posttransplant lymphoproliferative disorders (*see* Posttransplant lymphoproliferative disorders, pulmonary)

vascular resistance as contraindication to heart transplant, *Sept.*, 619

Pulse-pressure wave tracings: arterial, *Feb.*, 79

Q

Quality of life: and heart transplant, *Sept.*, 617-618

R

Rabbit antithymocyte globulin: in heart transplantation, *Sept.*, 650

Radial artery catheterization

complications of, *Feb.*, 81-90

thrombosis due to, *Feb.*, 85

Radiography

chest

in diagnosis of cardiac rejection, *Sept.*, 651

in posttransplant lymphoproliferative disorder, *June*, 425, 427

in dysphagia in esophageal carcinoma, *July*, 489-490

pulmonary lesions on, undiagnosed, as contraindication to heart transplant, *Sept.*, 620

Radiology

anomalies in desmoid tumor patients, *Apr.*, 277

localization of, *Apr.*, 279

in variceal bleeding, *Mar.*, 163-165

Radionuclide scanning: in splenic injuries, *Dec.*, 771-772

Radiotherapy

for carcinoma of esophagus and cardia (*see under* Carcinoma, esophagus and cardia)

for desmoid tumors, *Apr.*, 300

combined with surgery, complications after, *Apr.*, 306

injury causing axillary artery occlusion, *Jan.*, 39-40

- Radius: cortical thickening, in desmoid tumor patients, *Apr.*, 279
- Raynaud's disease, *Jan.*, 7-9
- Raynaud's phenomenon, *Jan.*, 9-10
- Reitamo syndrome, *Apr.*, 233-320
(See also Desmoid, tumors)
- Renal (see Kidney)
- Reserpine: in vasospastic disorders of upper extremity, *Jan.*, 27-28
- Resuscitation: in acute variceal bleeding, *Mar.*, 189-191
- Retroperitoneal area: CT of desmoid tumor in, *Apr.*, 292
- Rhabdomyoma: benign, differentiated from desmoid tumor, *Apr.*, 255
- Rheumatoid arthritis: digital vessels of upper extremity in, *Jan.*, 23
- Rib(s)
in desmoid tumor patient, *Apr.*, 299
- first, transaxillary approach to resection, for thoracic outlet compression syndrome, *Jan.*, 60
- Rupture (see Spleen, rupture)

S

- Sarcolemmal giant cells: in desmoid tumor, *Apr.*, 250
- Sarcoma (see Kaposi's sarcoma in renal transplant recipient)
- Scanning: radionuclide, in splenic injuries, *Dec.*, 771-772
- Schistosomiasis: variceal bleeding in, *Mar.*, 209
- Scleroderma: digital vessels of upper extremity in, *Jan.*, 18-20
- Sclerosis, endoscopic (see Sclerotherapy, endoscopic variceal)
- Sclerotherapy, endoscopic variceal, *Mar.*, 170-172
- complications of, *Mar.*, 172
- for prevention of recurrent bleeding, *Mar.*, 196-199
- Sepsis
prostacyclin release during, *Nov.*, 716-717
- prostaglandin(s) in, *Nov.*, 715-733
- effects of, *Nov.*, 718-725
- effects of, hemodynamic, *Nov.*, 722-723
- prostaglandin formation inhibition in, endogenous, *Nov.*, 718-722
- prostaglandin release during, *Nov.*, 715-718
- classic, *Nov.*, 715-716
- thromboxane release during, *Nov.*, 717-718
- Septic shock: clinical, prostaglandins in, *Nov.*, 725-728
- Sex steroid hormone receptors: in desmoid tissue, *Apr.*, 285-289
- Shock
circulatory, pharmacologic modulation by prostaglandins, *Nov.*, 723-725
- prostacyclin release during, *Nov.*, 716-717
- prostaglandin(s) in, *Nov.*, 715-733
- effects of, *Nov.*, 718-725
- effects of, hemodynamic, *Nov.*, 722-723
- prostaglandin formation inhibition in, endogenous, *Nov.*, 718-722
- prostaglandin release during, *Nov.*, 715-718
- classic, *Nov.*, 715-716
- septic, clinical, prostaglandins in, *Nov.*, 725-728
- thromboxane release during, *Nov.*, 717-718
- Shunts
mesoatrial, for Budd-Chiari syndrome, *Mar.*, 213
- peritoneovenous, in ascites, *Mar.*, 216
- portacaval, end-to-side, schematic of, *Nov.*, 173
- portal systemic, total
- in ascites, *Mar.*, 216
- side-to-side, examples of, *Mar.*, 174

- in variceal bleeding, *Mar.*, 172-177
 - in variceal bleeding, for prevention of recurrent bleeding, *Mar.*, 199-201
 - splenorenal, distal, *Mar.*, 177
 - arteriogram after, mesenteric, *Mar.*, 182
 - catheterization, in variceal bleeding, *Mar.*, 167
 - operative steps in, *Mar.*, 179-181
 - for prevention of recurrent variceal bleeding, *Mar.*, 201-202
 - Sinus tachycardia: during pulmonary artery catheterization, *Feb.*, 113
 - Skin lesions: in Kaposi's sarcoma in renal transplant recipient, *June*, 434
 - Smokers: esophageal cancer in, *July*, 483
 - Southern blotting: for immunoglobulin gene rearrangements in posttransplant lymphoproliferative disorders, *June*, 451
 - Spironolactone: in ascites, *Mar.*, 215-216
 - Spleen
 - accessory, *Dec.*, 786-787
 - anatomy of, *Dec.*, 758-762
 - appearance of, gross, *Dec.*, 759
 - arteriography (see Arteriography, splenic)
 - development in dorsal mesogastrium, *Dec.*, 760
 - elevation, surgical, *Dec.*, 761
 - function after splenectomy, *Dec.*, 775-779
 - implantation of, *Dec.*, 801-805
 - injuries, *Dec.*, 757-832
 - arteriography in, splenic, *Dec.*, 770-771
 - causes of, *Dec.*, 762-768
 - diagnosis of, *Dec.*, 768-775
 - diagnosis of, conventional methods, *Dec.*, 768-769
 - external trauma causing, *Dec.*, 763
 - iatrogenic, *Dec.*, 763-766
 - implantation-transplantation in, *Dec.*, 801-805
 - management of, nonoperative, *Dec.*, 791-796
 - operative preservation of spleen for (see Spleen, operative preservation for splenic injuries)
 - peritoneal lavage in, diagnostic, *Dec.*, 769-770
 - radionuclide scanning in, *Dec.*, 771-772
 - tomography in, computed, *Dec.*, 772-774
 - types of, *Dec.*, 762-768
 - ultrasound in, diagnostic, *Dec.*, 771
 - mobilization
 - by division of lateral peritoneal ligaments, *Dec.*, 818
 - by division of splenorenal and splenophrenic ligaments, *Dec.*, 812
 - operative preservation for splenic injuries, *Dec.*, 796-801
 - clinical experience, *Dec.*, 796-799
 - experimental evidence for, *Dec.*, 799-801
 - repair, *Dec.*, 816-818, 819
 - resection, partial, *Dec.*, 816-818, 819
 - rupture
 - delayed, *Dec.*, 766-767
 - occult, *Dec.*, 767-768
 - surgical approach through ventricular midline abdominal incision, *Dec.*, 811
 - transplantation, *Dec.*, 801-805
- Splenectomy**
- cellular changes in blood after, *Dec.*, 788
 - gastric vessels in, short, division of, *Dec.*, 815
 - immunoglobulins and response of immunoglobulins to antigens after, *Dec.*, 775-777
 - infections after (see Postsplenectomy infections)
 - partial, *Dec.*, 796-801

Splenectomy (cont.)

(See also Spleen, operative preservation for splenic injuries)

properdin after, *Dec.*, 777

splenic function after, *Dec.*, 775-779

technique, *Dec.*, 810-816, 817

tuftsin after, *Dec.*, 777

Splenic

artery, major branches of, *Dec.*, 762

vessels

anterior approach to, by initial division of gastrocolic omentum, *Dec.*, 817

blunt dissection for exposure in posterior aspect of splenic hilus, *Dec.*, 813

ligation and division of, *Dec.*, 814

Splenicocolic ligament: division for splenectomy, *Dec.*, 816

Splenicophrenic ligaments: division for spleen mobilization, *Dec.*, 812

Splenorenal

ligaments, division for mobilization of spleen, *Dec.*, 812

shunts (see Shunts, splenorenal, distal)

Splenorrhaphy, *Dec.*, 796-801

(See also Spleen, operative preservation for splenic injuries)

Splenosis, *Dec.*, 787-791

Steroid(s)

corticosteroids in heart transplantation, *Sept.*, 648-649

sex steroid hormone receptors in desmoid tissue, *Apr.*, 285-289

Stomach

(See also Gastrointestinal)

as esophageal substitute after esophagogastrrectomy, *July*, 519-522

in Kaposi's sarcoma in renal transplant recipient, *June*, 436

preparation for pull-up into chest or neck, *Aug.*, 556

Streptokinase: in Paget-Schroetter syndrome, *Jan.*, 53-54

Stricture: caustic, and esophageal carcinoma, *July*, 484

Subclavian

artery

in arteritis, giant cell, *Jan.*, 39

in desmoid tumor patient, *Apr.*, 298

occlusive lesions, *Jan.*, 31-34

occlusive lesions, surgical correction, *Jan.*, 32-34

surgical exposure, *Jan.*, 34

steal, reconstructive procedure for, *Jan.*, 33

vein

catheterization, complications of, *Feb.*, 94-97

occlusion due to desmoid tumor, *Apr.*, 298

occlusion in thoracic outlet compression syndrome, *Jan.*, 50

Suppressor cells: transplantation and prostaglandins, *Nov.*, 739

Supraclavicular region: desmoid tumor in, *Apr.*, 297

Sympathectomy: for vasospastic disorders of upper extremity, *Jan.*, 28-29

Swallowing abilities: after therapies for cervical esophageal carcinoma, *Aug.*, 553

T

Tachycardia during pulmonary artery catheterization

sinus, *Feb.*, 113

ventricular, *Feb.*, 114

Tamponade for variceal bleeding, *Mar.*, 169-170

acute, *Mar.*, 192

Teeth: in desmoid tumor patients, *Apr.*, 278

Thoracic outlet syndrome, *Jan.*, 34-37

brachial artery thrombus from subclavian lesion in, *Jan.*, 35
collateral veins in, *Jan.*, 51

- operative correction, *Jan.*, 36-37
 rib resection for, first, transaxillary approach to, *Jan.*, 60
 subclavian vein occlusion in, *Jan.*, 50
- Thrombolytic therapy (see Paget-Schroetter syndrome, fibrinolytic therapy for)
- Thrombosis
 portal vein (see Variceal bleeding, in portal vein thrombosis)
 radial artery, due to catheterization, *Feb.*, 85
 ulnar artery, digital vessels in, *Jan.*, 27
- Thrombotic vegetation: endocardium and tricuspid valve, due to pulmonary artery catheterization, *Feb.*, 116
- Thromboxane
 actions of, *Oct.*, 682
 blockers, *Nov.*, 721
 in breast masses, female, *Oct.*, 695
 release during sepsis and shock, *Nov.*, 717-718
 in shock, septic, *Nov.*, 727
- Thrombus
 brachial artery
 after cardiac catheterization, *Jan.*, 44
 from subclavian lesion in thoracic outlet syndrome, *Jan.*, 35
 formation due to pulmonary artery catheterization, *Feb.*, 120-123
- Thyroid: in desmoid tumor patient, *Apr.*, 299
- Tomography, computed
 of desmoid tumor in retroperitoneal area, *Apr.*, 292
 in splenic injuries, *Dec.*, 772-774
- Toxoplasmosis: after heart transplant, *Sept.*, 659
- Transfusion-induced immunosuppression: and prostaglandins, *Nov.*, 739
- Transplantation
 antigen stimulation, prostaglandin release by, *Nov.*, 733
 antilymphocyte globulin in, Minnesota, *June*, 389
 FK506 in, *June*, 389
 heart (see below)
 kidney (see Kaposi's sarcoma in renal transplant recipient)
 liver, for variceal bleeding, *Mar.*, 184-187
 methods, *Mar.*, 186, 187, 188
 for prevention of recurrent bleeding, *Mar.*, 204
 lymphoproliferative disorders after (see Posttransplant lymphoproliferative disorders)
 OKT3 in, *June*, 387, 389
 prostaglandins in (see Prostaglandins, in transplantation)
 recipients, iatrogenic immunodeficiency state of, *June*, 386-389
 spleen, *Dec.*, 801-805
 Transplantation, heart, *Sept.*, 613-672
 antithymocyte globulin in, rabbit, *Sept.*, 650
 appearance of heart at end of transplant procedure, *Sept.*, 632
 arteriosclerosis after, accelerated graft, *Sept.*, 659-660
 azathioprine in, *Sept.*, 649-650
 brain death and, *Sept.*, 625, 628-629
 bridge to transplantation, *Sept.*, 663-664
 coccidioidomycosis after, *Sept.*, 659
 complications after, *Sept.*, 657-661
 psychosocial, *Sept.*, 661
 contraindication(s) to, *Sept.*, 618-621
 age as, *Sept.*, 618-619
 cachexia as, *Sept.*, 620
 diabetes mellitus as, *Sept.*, 620
 hepatic dysfunction as, irreversible, *Sept.*, 619
 inability to comply with medical therapy as, *Sept.*, 620
 malignancy as, *Sept.*, 621

Transplantation, heart (*cont.*)

- other organ transplant as,
Sept., 620
- peptic ulcer disease as, *Sept.*,
621
- pulmonary infarction as, unre-
solved, *Sept.*, 619-620
- pulmonary lesions as, undi-
agnosed radiographic, *Sept.*,
620
- pulmonary vascular resistance
as, *Sept.*, 619
- renal dysfunction as, irrevers-
ible, *Sept.*, 619
- corticosteroids in, *Sept.*, 648-649
- cyclosporine in, *Sept.*, 644-648
- cytotoxic screen in, *Sept.*, 622
- donor, *Sept.*, 622-627
 - anatomy of donor heart prior
to implantation, *Sept.*, 631
- donor care, *Sept.*, 629
- donor selection, *Sept.*, 624-627
 - absence of other factors, *Sept.*,
626-627
 - age and, *Sept.*, 625
 - anticipated ischemic time and,
Sept., 627
 - brain death and, *Sept.*, 625
 - criteria for, *Sept.*, 625-626
 - inotropic support and, *Sept.*,
626
- electrophysiology after, *Sept.*,
635-636
- etiologies of cardiac disease lead-
ing to, *Sept.*, 616
- future of, *Sept.*, 663-664
- heart metabolism after, *Sept.*,
636-637
- heart physiology after, *Sept.*,
634-637
- heart rate after, *Sept.*, 634-635
- hemodynamics after, *Sept.*, 635
- heterotopic, technique and cri-
tique of, *Sept.*, 633
- history, *Sept.*, 613-616
- immunity and, *Sept.*, 638-642
- immunosuppression in, *Sept.*,
642-644
 - quadruple therapy, *Sept.*, 644,
645

- quadruple therapy, survival af-
ter, *Sept.*, 638
- immunosuppressive agents in,
Sept., 644-650
- infection after, *Sept.*, 657-659
 - prevention, diagnosis and treat-
ment of, *Sept.*, 657-658
- probability of freedom from, in
quadruple therapy patients,
Sept., 639
- matching requirements with do-
nor, *Sept.*, 621-622
- ABO blood group compatibility,
Sept., 621-622
- size, *Sept.*, 621
- mediastinitis after, *Sept.*, 658-659
- modern era of, time line for,
Sept., 614
- mortality after, *Sept.*, 616
- number by year since 1973, *Sept.*,
615
- orthotopic, *Sept.*, 629-631
 - procedure, *Sept.*, 629-631
- recipient selection, *Sept.*,
616-621
 - considerations after, *Sept.*,
621-622
 - functional ability and, *Sept.*,
616-617
 - prognosis and, *Sept.*, 616-617
 - quality of life and, *Sept.*,
617-618
- rejection
 - acute, and immunity, *Sept.*,
640-642
 - diagnosis (*see below*)
 - hyperacute, and immunity,
Sept., 638-640
 - immunology of, *Sept.*, 637-638
 - probability of freedom from, in
quadruple therapy patients,
Sept., 639
- rejection, diagnosis, *Sept.*,
650-656
- clinical approach, *Sept.*, 651-654
- cytoimmunologic monitoring
in, *Sept.*, 655
- electrocardiogram in, surface,
frequency analysis of, *Sept.*,
656

- endomyocardial biopsy in, *Sept.*, 651-654
 - history in, *Sept.*, 651
 - isovolumic relaxation time in, *Sept.*, 654-655
 - noninvasive, *Sept.*, 654-656
 - physical examination in, *Sept.*, 651
 - prolactin in, serum, *Sept.*, 655-656
 - roentgenogram in, chest, *Sept.*, 651
 - urinary polyamines in, *Sept.*, 655
 - survival after, *Sept.*, 662-663
 - sympathetic control mechanisms after, *Sept.*, 636-637
 - technical safeguards in, *Sept.*, 631-633
 - toxoplasmosis after, *Sept.*, 659
 - xenotransplantation, *Sept.*, 664
 - Trauma
 - axillary artery, causing occlusion, *Jan.*, 40
 - desmoid tumors and, *Apr.*, 274-275
 - occupational, digital vessels of upper extremity in, *Jan.*, 26-27
 - spleen (*see Spleen, injuries*)
 - Traverso and Longmire's pancreatoduodenectomy, *May*, 334
 - Tricuspid valve
 - erosion due to Swan-Ganz catheter, *Feb.*, 115
 - thrombotic vegetation due to pulmonary artery catheterization, *Feb.*, 116
 - Tufts: after splenectomy, *Dec.*, 777
 - Tumor(s)
 - cell(s)
 - differentiation, and prostaglandins, *Oct.*, 687-689
 - in vitro, and eicosanoids, *Oct.*, 683-689
 - prostaglandin production by, *Oct.*, 683-686
 - replication, effects of prostaglandins on, *Oct.*, 686-687
 - desmoid (*see Desmoid, tumors*)
 - doubling times related to prostaglandin biosynthesis rates, *Oct.*, 686
 - Epstein-Barr virus and, *June*, 376-409
 - growth control in vivo, and prostaglandins, *Oct.*, 697-700
 - in immunodeficiency states, *June*, 385
 - in vivo
 - eicosanoids and, *Oct.*, 694-700
 - prostaglandin production by, *Oct.*, 694-695
 - lymphoid (*see Lymphoid tumors*)
 - TxA₂ (*see Thromboxane*)
 - Tylosis: and esophageal carcinoma, *July*, 484
- U**
- Ulcer disease: peptic, as contraindication to heart transplant, *Sept.*, 621
 - Ulnar artery thrombosis: digital vessels in, *Jan.*, 27
 - Ultrasound: diagnostic, in splenic injuries, *Dec.*, 771
 - Ultrastructural investigation: of desmoid tumors, *Apr.*, 249
 - Urinary polyamines: in diagnosis of acute cardiac rejection, *Sept.*, 655
 - Urokinase: in Paget-Schroetter syndrome, *Jan.*, 53, 54
- V**
- Vaccination
 - causing overwhelming postsplenectomy infection, *Dec.*, 808-809
 - preventing overwhelming postsplenectomy infections, *Dec.*, 806-808
 - Vaccines: for overwhelming postsplenectomy infections, *Dec.*, 809
 - Valve (*see Tricuspid valve*)

Variceal bleeding

acute

- endoscopy in, *Mar.*, 191
- management of, *Mar.*, 189-192
- pitressin in, *Mar.*, 191-192
- resuscitation in, *Mar.*, 189-191
- tamponade in, *Mar.*, 192
- biopsy in, liver, *Mar.*, 162-163
- Child's classification, *Mar.*, 161-162
- decompression for, selective, *Mar.*, 177-183
- devascularization procedures for, *Mar.*, 183-184
- diagnosis of, *Mar.*, 159-168
 - biochemical, *Mar.*, 161
 - clinical, *Mar.*, 160
 - endoscopic, *Mar.*, 162
 - hematologic, *Mar.*, 160-161
- first bleed, prophylactic therapy for prevention of, *Mar.*, 204-206
- hemodynamic measurements in, *Mar.*, 165-167
- hepatocyte function in, quantitative, *Mar.*, 167-168
- liver transplantation for, *Mar.*, 184-187
 - methods, *Mar.*, 186, 187, 188
 - management of, *Mar.*, 187-209
- operation for, emergency, *Mar.*, 192
- pharmacotherapy for, *Mar.*, 168-169
- in portal vein thrombosis, extrahepatic, *Mar.* 206-209
- arteriogram in, mesenteric, *Mar.*, 207
- management schema, *Mar.*, 208
- radiology in, *Mar.*, 163-165
- recurrent, prevention of, *Mar.*, 193-204
 - decompression for, selective, *Mar.*, 201-202
- devascularization procedures for, *Mar.*, 203
- liver transplantation for, *Mar.*, 204
- pharmacotherapy for, *Mar.*, 194-195

propranolol for, *Mar.*, 195

schema for, *Mar.*, 205

shunts for, total portal systemic, *Mar.*, 199-201

in schistosomiasis, *Mar.*, 209

sclerotherapy for (*see* Sclerotherapy, endoscopic variceal)

shunts for

portal systemic, total, *Mar.*, 172-177

splenorenal (*see* Shunts, splenorenal, distal)

in specialized conditions, *Mar.*, 206-209

tamponade for, *Mar.*, 169-170

treatment of, *Mar.*, 168-187

Vasculitis, upper extremity digital vessels in, *Jan.*, 20-23

diagnosis, *Jan.*, 22

hypersensitivity, *Jan.*, 23

therapy, *Jan.*, 23

spectrum of, *Jan.*, 21

systemic, fingertip and nail fold infarcts in, *Jan.*, 24

Vaso-occlusive disorders of upper extremity, *Jan.*, 7-67

digital (*see* Digital, vessel occlusion, upper extremity)

small artery, *Jan.*, 7-18

algorithm in, clinical, *Jan.*, 15

arteriography in (*see* Arteriography, in small artery occlusive disorders of upper extremity)

epidemiology of, *Jan.*, 17-18

noninvasive tests in, *Jan.*, 10-15

Vegetations: thrombotic, on tricuspid valve and endocardium due to pulmonary artery catheterization, *Feb.*, 116

Vein

axillosubclavian, repair in Paget-Schroetter syndrome, transclavicular approach for, *Jan.*, 58-59

central venous catheterization (*see* Catheterization, central venous)

collateral, in thoracic outlet syndrome, *Jan.*, 51

- jugular, internal, catheterization, complications of, *Feb.*, 95-97
- occlusive disorders of upper extremity, *Jan.*, 44-60
- iatrogenic, *Jan.*, 47-48
- portal (see Portal, vein)
- subclavian (see Subclavian, vein)
- Ventricle
 - left, end diastolic volume, and PAWP during pulmonary artery catheterization, *Feb.*, 123-124
 - tachycardia during pulmonary artery catheter removal, *Feb.*, 114
- Vertebral artery laceration: due to attempted central venous catheterization, *Feb.*, 96
- Vessels
 - (See also Vaso-occlusive disorders of upper extremity)
 - brachiocephalic, reconstruction techniques using, *Jan.*, 32
 - ditital (see Digital, vessel occlusion, upper extremity)
 - gastric, short, division for splenectomy, *Dec.*, 815
 - great, after cardiectomy, *Sept.*, 630
 - intravascular devices, infection complicating, *Feb.*, 124-130
 - pulmonary vascular resistance as contraindication to heart transplant, *Sept.*, 619
 - splenic (see Splenic, vessels)
- Virus (see Epstein-Barr virus)

W

- Walker carcinosarcoma: effects of cyclooxygenase inhibition on, *Oct.*, 693
- Watson's pancreatoduodenectomy, *May*, 334
- Whipple's pancreatoduodenectomy, *May*, 331
- Witzel jejunostomy, *Aug.* 547

X

- Xenografting: cardiac, *Sept.*, 664